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overexpression was characteristically observed in squa-
mous cell carcinomas of the lung, esophagus, and head 
and neck region. Additionally, overexpression of TP63 and 
TP73 was frequently observed in thymomas. Our results 
reveal a spectrum of genomic alterations in the TP53 path-
way that is characteristic of many tumor types, and these 
data may be useful in the trials of targeted therapies.
Keywords Cancer · Gene expression profiling · Japanese 
population · TP53 pathway · Whole exome sequencing
Introduction
Genome sequencing is an essential tool for cancer research 
that leads to important biological discoveries and allows for 
the systematic classification of mutations based on cellu-
lar signal transduction pathways [1, 2]. Furthermore, data 
accumulated from studies using tumor tissues of patients 
with cancer has led to the identification of somatic altera-
tions in many cancer-related genes [3, 4]. The TP53 gene 
encodes a tumor suppressor and frequently undergoes 
somatic mutation in tumor cells [5]. A database of TP53 
mutations is available [6, 7], and there are detailed data 
regarding the functional activities of TP53 mutants.
TP53 mediates diverse cellular functions, including the 
response to DNA damage and induction of cell cycle arrest, 
cellular senescence, autophagy, and apoptosis [8–10]. 
Additionally, TP53 can regulate the cellular metabolism 
[11], inhibit stem cell self-renewal, and control the repro-
graming of differentiated cells into stem cells [8]. TP53 
has also been shown to mediate tumor metastasis and inva-
sion [12]. The disruption of signaling pathways that acti-
vate TP53 play an important role in tumor progression. 
Although TP53 knockout mice develop normally, their 
Abstract The TP53 signal transduction pathway is an 
attractive target for cancer treatments. In this study, we 
conducted a comprehensive molecular evaluation of 907 
patients with cancer in Japan to identify genomic altera-
tions in the TP53 pathway. TP53 mutations were frequently 
detected in many cancers, except melanoma, thymic 
tumors, gastrointestinal stromal tumors, and renal cancers. 
The frequencies of non-synonymous single nucleotide 
variants (SNVs) in the TP53 family members TP63 and 
TP73 were relatively low, although genes with increased 
frequencies of SNVs were as follows: PTEN (11.7%) in 
breast cancer, CDKN2A (11.1 and 9.6%) in pancreas and 
head and neck cancers, and ATM (18.0 and 11.1%) in liver 
and esophageal cancers. MDM2 expression was decreased 
or increased in patients with mutant or wild-type TP53, 
respectively. CDKN1A expression was increased with 
mutant TP53 in head and neck cancers. Moreover, TP63 
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susceptibility to cancers is higher than wild-type TP53 ani-
mals [13]. TP53 germline mutations in humans are associ-
ated with increased susceptibility to cancer and an earlier 
age of onset compared to TP53 wild-type controls [14]. 
Li-Fraumeni syndrome is a rare, inherited, and highly pen-
etrant disorder that predisposes individuals to cancer. This 
syndrome is characterized by autosomal dominant TP53 
germline mutation [15]. Thus, exploiting the tumor sup-
pressor function of TP53 and the high frequencies of TP53 
mutations in cancer tissues represents an appealing thera-
peutic strategy for developing cancer treatments. However, 
despite numerous attempts to target the TP53 pathway [16, 
17], there are currently no treatments available in the clinic 
[5].
TP53 activity is regulated by the E3 ubiquitin pro-
tein ligase and proto-oncoprotein murine double min-
ute 2 (MDM2) and by post-translational modifications, 
such as phosphorylation and acetylation. MDM2 inhibits 
TP53 transcriptional activity by binding to the N-terminal 
domain of TP53, which leads to downregulation of the 
TP53 pathway [18]. Overexpression of MDM2 in mice 
revealed a TP53-independent role in tumorigenesis [19], 
and MDM2 overexpression or amplification occurs in 
many human cancers and contributes to oncogenesis [20, 
21]. Previous studies have demonstrated that inhibiting 
MDM2-TP53 binding in xenograft models restores TP53 
function and can inhibit tumor cell proliferation and induce 
apoptosis [22]. However, the data indicate that the mecha-
nisms underlying these effects are associated with the more 
complex regulation of MDM2 expression. Although many 
TP53-associated molecules play important roles in regulat-
ing TP53 transcription [8, 23], the regulatory mechanisms 
underlying its activation in vivo have not been fully eluci-
dated. In this study, we present a comprehensive analysis of 
genomic alterations that are associated with the TP53 path-
way in various tumors in a Japanese population. We ana-
lyzed tumor tissues and adjacent normal tissues and blood 
samples to identify tumor-specific somatic mutations. We 
anticipate that this comprehensive analysis will lead to the 
development of individualized treatment strategies.
Materials and methods
Subjects
The Shizuoka Cancer Center (Shizuoka, Japan) launched 
Project HOPE in late January 2014. The project objective 
is to improve cancer medicine [24]. As a component of this 
project, we performed whole exome sequencing (WES) 
using blood samples and fresh surgical specimens. We 
then conducted comprehensive analyses of gene expres-
sion using matched tumor and adjacent normal tissues from 
each patient. Tumor-specific single nucleotide variants 
(SNVs) were determined by comparing tumor tissue with 
blood cell data from the same patient. The characteristics 
of the subjects are summarized in Table 1, and the detailed 
histpathological characteristics are presented in Supple-
mentary Table 1. The research plan was designed according 
to the revised Ethical Guidelines for Human Genome/Gene 
Analysis Research in Japan (http://www.lifescience.mext.
go.jp/files/pdf/n1115_01.pdf) and was approved by the 
Institutional Review Board of the Shizuoka Cancer Center. 
All patients provided written informed consent.
DNA preparation
We obtained blood and tumor samples from 907 patients 
with cancer at the time of surgery. Surgeries were per-
formed at the Shizuoka Cancer Center Hospital between 
January 2014 and March 2015. Sample genomic DNA 
was extracted from whole blood and tumor tissues using 
a QIAamp DNA Mini kit (Qiagen, Hilden, Germany). 
DNA was quantified using a Nanodrop spectrophotometer 
(Thermo Fisher Scientific, Wilmington, DE, USA) and a 
Qubit 2.0 fluorometer (Thermo Fisher Scientific). AcroMe-
trix Oncology Hotspot Control DNA (Thermo Fisher Sci-
entific) was used as the standard.
RNA preparation
Fresh tumor and adjacent normal tissue were soaked in 
RNAlater reagent (Qiagen). The total RNA was then iso-
lated and purified using an RNeasy Mini kit (Qiagen) 
according to the manufacturer’s protocol. Total RNA 
was analyzed using a Nanodrop 2000 spectrophotometer 
(Thermo Fisher Scientific) and gel electrophoresis. The 
RNA quality was evaluated using gel electrophoresis and 
the  A260/A280 value. The RNA integrity number (RIN) [25] 
was determined using an Agilent 2100 Bioanalyzer (Agi-
lent Technologies, Santa Clara, CA, USA). We used RNA 
samples with an  A260/A280 > 1.8 and a RIN > 6.0 for gene 
expression analysis.
Whole exome sequencing (WES)
We performed WES using an Ion Proton System equipped 
with a PI chip V2 together with an AmpliSeq Exome kit 
(Thermo Fisher Scientific) [26]. Briefly, 100  ng each of 
tumor and matched blood cell DNA was used for tar-
get amplification with the following protocol: 99 °C for 
2 min, followed by 10 cycles at 95 °C for 15  s and 60 °C 
for 16  min, and a final hold at 10 °C. The incorporated 
primer sequences were partially digested using FuPa Rea-
gent (Thermo Fisher Scientific). Ion Torrent Proton adapt-
ers were ligated to the amplicons at 22 °C for 30 min and 
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Fig. 1  Analysis of gene 
expression profiles of 19 tumor 
types. Heat map showing 14 of 
the TP53 pathway-associated 
genes that were differentially 
expressed in tumor tissues rela-
tive to adjacent normal tissues. 
The expression levels  (log2) 
were normalized for each gene 
and are shown by the graded 
color scale, with red and blue 
representing high and low 
expressions, respectively. White 
squares indicate the expression 
levels (absent call) for which 
the fold change (FC) could not 
be calculated, as described in 
Methods. TP53 status (bottom) 
is indicated by dark green and 
white squares that indicate 
the presence and absence of 
mutations, respectively. Yellow 
bars with numbers beneath 
the graphs indicate squamous 
cell carcinomas of the lung, 
esophagus, and head and neck 
region. Bright green bars with 
numbers (bottommost) indicate 
thymoma cases in thymus. 
a Colon (n = 163), rectum 
(n = 148); b lung (n = 176); c 
stomach (n = 116); d esophagus 
(n = 18); e liver (n = 61); f 
breast (n = 60); g head & neck 
(n = 73); h sarcoma (n = 16); 
i pancreas (n = 18); j kidney 
(n = 13); k GIST (n = 9); l 
uterus (n = 12); m thymus 
(n = 6); n melanoma (n = 5); o 
ovary (n = 4); p brain (n = 3); q 
skin (n = 3); r bile duct (n = 2); 
s gallbladder (n = 1). The 
bottommost number shows an 
individual tumor
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then at 72 °C for 10 min. The amplicon library was purified 
using Agencourt AMPure XP Beads (Thermo Fisher Scien-
tific). The library DNA was quantified by qRT-PCR, and 7 
pM library DNA was used for sequencing. The sequencing 
data were aligned to the human reference genome (assem-
bly GRCh37/hg19) and were quality trimmed using Ion 
Torrent Suite version 4.2 (Thermo Fisher Scientific). The 
mutations were visualized using the Integrative Genomics 
Viewer [27] and were validated using Sanger sequencing or 
pyrosequencing.
Validation of somatic mutations using deep sequencing 
of the Custom Cancer Panel (CCP)
The candidate mutations identified by WES were vali-
dated using the Ion Torrent PGM AmpliSeq Custom Panel 
(Themo Fisher Scientific) for 409 target genes (the target 
genes are available at https://www.thermofisher.com). We 
used a 200-bp standard DNA option to design the AmpliSeq 
primers. Sample DNA was diluted to 10 ng/µL, and 1 µL 
was used to prepare the amplicon library according to the 
manufacturer’s protocol (Themo Fisher Scientific). The tar-
get sequences were amplified using the customized primers 
and were then partially digested. The adapters and barcodes 
were ligated to the amplicons, which were then purified 
using the Agencourt AMPure XP reagent (Thermo Fisher 
Scientific). The libraries were sequenced using the same 
method described above for WES.
Comprehensive gene expression analysis using a DNA 
microarray
Cyanin-3 (Cy3)-labeled cRNA was prepared from 100 ng 
of RNA using a One-color Low Input Quick Amp Labeling 
kit (Agilent Technologies) according to the manufacturer’s 
instructions, and the RNA was purified using an RNeasy 
Mini kit (Qiagen). Dye incorporation and the cRNA yield 
were evaluated using the Nanodrop 2000 spectrophotom-
eter. Cy3-labeled cRNA was hybridized to SurePrint G3 
Human GE version 2.0 containing 50,599 probes (Agilent 
Technologies) for 17 h at 65 °C while rotating in an Agilent 
hybridization oven. After hybridization, the microarrays 
were washed for 1 min at room temperature with GE Wash 
Buffer 1 (Agilent Technologies) and for 1 min at 37 °C with 
GE Wash Buffer 2 (Agilent Technologies). The microarrays 
were then dried using the Agilent stabilization and drying 
solution. The slides were scanned using an Agilent DNA 
microarray scanner immediately after washing [28]. The 
scanned images were quantitated using GeneSpring version 
13.1.1 software (Agilent Technologies) to generate raw sig-
nal intensity data. The raw signals were log-transformed 
and normalized (GeneSpring software). The difference in 
the normalized microarray signal intensities (fold change) 
between the tumor and adjacent normal tissue were then 
calculated [29].
Results
We used WES to analyze 18,835 genes in paired tumor 
tissue and blood samples to detect genetic changes in 19 
different tumors. Simultaneously, we used the CCP com-
prising 409 target genes to conduct deep sequencing of 
tumor tissue samples. The mean depth of coverage of the 
target regions was 118-fold for WES and 1,101-fold for 
the CCP. We detected the following 9,439 non-synon-
ymous single nucleotide variants (SNVs) by WES and 
CCP using 409 target genes in 907 patient tumors: 6,889 
missense, 858 nonsense, 229 splice site, 1309 frameshift, 
and 154 other mutations. The genes listed in Supplemen-
tary Table 2 are classified as oncogenes or tumor suppres-
sor genes according to Vogelstein et al. [30]. If there were 
multiple mutations found in a gene, then all of the muta-
tions were counted. There are 30 genes, including BRCA1 
and BRCA2, that are not involved in the CCP (the genes 
are marked by an asterisk in Supplementary Table 2). The 
non-synonymous SNVs of well-annotated cancer genes, 
such as PIK3CA, APC, KRAS, CTNNB1, FBXW7, GATA3 
and VHL, and TP53, were consistent with those of previous 
studies [3, 4, 31].
Somatic mutations in TP53 were the most frequently 
detected (52.7%) in the set of cancer-related genes. The fre-
quencies of missense, nonsense, frameshift, and splice site 
somatic mutations in TP53 were 72.0, 14.2, 8.2, and 5.6%, 
respectively. The tumor frequencies were the following: 
colorectum (72.0%), esophagus (61.1%), stomach (59.5%), 
head and neck (57.5%), lung (48.9%), and pancreas (38.9%) 
(Table 2). There were no TP53 mutations detected in renal 
cancer, melanoma, thymic tumor, or gastrointestinal stro-
mal tumor (GIST). The data indicate that 92.5% of the 
somatic mutations were identified in the DNA-binding 
domain of TP53.
The frequencies of somatic mutations in members of 
the TP53 family and its related genes were low (Table 2). 
However, we detected increased frequencies of somatic 
mutations among genes encoding components of the TP53 
signaling pathway (Table  3). These genes are important 
and well-established genes for p53-associated responses [8, 
9]. The mutation data include the following: PTEN (11.7 
and 8.7%) in breast and colorectal cancer; ATM (18.0 and 
11.1%) in liver and esophagus cancer; CDKN2A (11.1 and 
9.6%) in pancreas and head and neck cancer; and ATM 
(50.0%), ATR (41.7%), PTEN (83.3%), RB1 (41.7%), and 
EP300 (33.3%), which is an acetyltransferase (HAT) asso-
ciated with TP53 acetylation [32], in uterine cancer. We 
detected the wild-type pleckstrin homology-like domain 
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family member 3 (PHLDA3), which is a TP53-regulated 
repressor of AKT [33], and the TP53-upregulated modula-
tor of apoptosis (PUMA) in all samples.
Possible interactions between the TP53-related muta-
tions and smoking status were examined in the strati-
fied analyses (Supplementary Table  3). Among them, the 
TP53 mutation in smoking status was found to be associ-
ated with lung cancers in a statistically significant manner 
(P = .0169). One limitation of the present study is that we 
had insufficient information on the drinking status of the 
enrolled subjects. Possible interactions with smoking sta-
tus, and other environmental/lifestyle-related factors need 
to be evaluated in further studies.
We next used microarrays to conduct gene expression 
profiling analysis on pairs of tumors and adjacent normal 
tissue (Fig. 1). The following genes were overexpressed in 
various tumors: CCND1 in colorectal and renal cancers, 
and sarcoma; CCNE1 in colorectal, lung, stomach, esopha-
gus, head and neck, uterine and ovarian cancers, and sar-
coma; and CDKN2A in lung, uterine, and ovarian cancers. 
PHLDA3 expression was decreased in breast and rectal can-
cer. However, PHLDA3 was increased in renal cancer and 
GIST. The expression level of AKT1 was decreased in renal 
cancer and GIST. The expressions BAX and PUMA were 
increased in the majority of samples. TP53 overexpression 
was detected in colorectal cancer and TP63 overexpression 
was characteristically detected in squamous cell carcinoma 
of the lung, esophagus, and tumors in the head and neck 
region. Moreover, the expression levels of TP53, TP63, and 
TP73 were increased at high frequency in thymomas.
We compared the expression levels of the most impor-
tant TP53-responsive genes MDM2 and CDKN1A (encod-
ing p21) based on TP53 status (Fig. 2). This analysis indi-
cated that MDM2 was consistently expressed at a high level 
in the surgical specimens of renal cancer, thymic tumor, 
and GIST. However, somatic mutations in TP53 were not 
detected. In patients with other cancer types, the absence of 
a somatic mutation in TP53 was commonly associated with 
increased MDM2 expression, except colorectal cancers. In 
contrast, the presence of somatic mutations in TP53 was 
associated with decreased MDM2 expression. While the 
expression levels of CDKN1A were increased in surgical 
specimens from the esophagus and head and neck cancers 
with a mutated TP53 gene, the expression levels were unre-
lated to the TP53 status in patients with other cancer types.
Discussion
Genes encoding downstream components of the TP53 
signaling pathway were identified in studies using vari-
ous inducible promoters in cancer cell lines, gene silenc-
ing, and transgenic knock-in models [34]. Additionally, 
recent extensive cancer genome analyses have revealed that 
numerous genes encoding components of the TP53 path-
way are altered in human cancers. These findings suggest 
that the TP53 pathway plays a critical role in a range of 
malignancies [9]. These are currently a limited number of 
studies examining gene expression simultaneously in fresh 
tissues from multiple tumor types in a Japanese population 
to determine TP53 status or mutations in genes encoding 
components of the pathway.
In the present study, we detected TP53 mutations and 
other genetic abnormalities in the TP53 pathway in many 
tumors. We were intrigued that our microarray analy-
sis revealed that MDM2 was frequently expressed at high 
levels in patients with wild-type TP53. We assume in 
these patients that MDM2 formed a complex with wild-
type TP53 and inhibited the ability of TP53 to activate 
transcription of its target gene(s). The overexpression of 
MDM2 promotes cell proliferation and tumorigenesis and 
is correlated with poor clinical outcomes [35]. The inac-
tivation of MDM2 is essential for the activation of TP53. 
Thus, MDM2 may represent an independent target for drug 
development. For example, Tovar et  al. [36] reported that 
the small molecule RG7112 acts as an MDM2 antagonist 
and showed potent antitumor activity in tumors expressing 
wild-type TP53 in xenograft mouse models. In addition, we 
detected CDKN1A overexpression in tumors of the colorec-
tum, head and neck, esophagus, and stomach with mutated 
TP53. CDKN1A is a key regulator of the cell cycles, cell 
death, DNA repair, and cell motility [37]. Several studies 
have indicated that the CDKN1A overexpression is corre-
lated with poor prognosis in different cancers, including 
esophageal carcinoma [38, 39]. Thus, identifying target 
molecules based on TP53 status may facilitate the stratifi-
cation of patients and development of more effective tar-
geted therapies. TP63 is frequently expressed in squamous 
cell carcinomas of the lung, head and neck region, and 
esophagus [40–42]. In this study, we detected high lev-
els of TP63 expression in patients with these carcinomas. 
Moreover, we demonstrate that TP53, T63, and TP73 were 
frequently expressed in thymomas. There are a limited 
number of reports describing the gene expressions in thy-
moma patients [43]. TP63 and TP73 encode a C-terminal 
sterile-alpha-motif domain that is not present in TP53. This 
domain is important for protein–protein interactions and 
is associated with regulating development [44]. The tran-
scription factors TP63 and TP73 are phosphorylated and 
play important roles in the activation of transcription genes 
controlling apoptosis [45]. TP63 also has essential roles in 
embryogenesis and in the maintenance and differentiation 
of epithelial stem cells [46, 47]. TP63 and TP73 are over-
expressed in human cancers, and their loss affects tumor 
progression and metastasis [45]. Moreover, abnormal splic-
ing caused by TP63/TP73 overexpression is frequently 
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observed in human malignancies and is associated with 
poor clinical outcomes [44]. Thus TP63/TP73 may be 
promising new targets for treating thymomas.
In this study, we used WES and global gene expres-
sion profiling to reveal the types of genetic abnormalities 
that occur in Japanese patients with cancer. Several types 
of cancer-acquired mechanisms result in the inactiva-
tion of the TP53 or components of its signal transduction 
pathway. Thus, restoration of the TP53-mediated tumor 
suppression system could serve as a key strategy for pre-
venting tumor development and progression. Understand-
ing how target genes are involved in the TP53 pathway in 
many tumor types is essential for selecting patients who 
will respond to cancer therapy. We expect that our study 
will lead to further functional characterization of genes in 
the context of TP53-based individualized therapy.
Acknowledgements We thank Mami Mizuguchi and Fukumi Kam-
ada for their excellent contributions and the staff at the Shizuoka Can-
cer Center Hospital for clinical support and sample preparation.
Conflict of interest The authors have no conflict of interest to 
declare.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 









































































Incre. Decre. Incre. Decre.
a MDM2 CDKN1A MDM2 CDKN1A MDM2 CDKN1A









Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre.
noisserpxEnoisserpxE
MDM2 CDKN1A MDM2 CDKN1A MDM2 CDKN1A MDM2 CDKN1A
Expression
Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre.
noisserpxEnoisserpxEnoisserpxE
Expression
Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre. Incre. Decre.
noisserpxEnoisserpxEnoisserpxE
MDM2 CDKN1A MDM2 CDKN1A MDM2 CDKN1A MDM2 CDKN1A













Fig. 2  Correlations between the TP53 status and MDM2 or CDKN1A 
expression levels in various tumor types. The TP53 status is indi-
cated as mutated (+) or non-mutated (−). In each case, the MDM2 or 
CDKN1A expression level is denoted as the number of tumor tissues 
with increased (red) or decreased (blue) expression relative to adja-
cent normal tissues, as described in Methods. a Colorectum (n = 311); 
b lung (n = 176); c stomach (n = 116); d esophagus (n = 18); e liver 
(n = 61); f breast (n = 60); g head & neck (n = 73); h sarcoma (n = 16); 
i pancreas (n = 18); j kidney (n = 13); k GIST (n = 9); l uterus 
(n = 12); m thymus (n = 6); n melanoma (n = 5); o others (n = 13). 
Others were as follows: ovary (n = 4), brain (n = 3), bile duct (n = 2), 
skin (n = 3), and gallbladder (n = 1). Somatic TP53 mutations were 
not detected in kidney, GIST, thymus, and melanoma
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link to the Creative Commons license, and indicate if changes were 
made.
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